BPC-157 (Body Protection Compound 157) is a 15-amino-acid research peptide originally derived from a gastric-juice protein fragment, characterised principally by Predrag Sikiric's research group at the University of Zagreb across multiple decades of preclinical research work. The programme's scope spans gastrointestinal repair, wound healing, tendon-and-ligament healing, vascular endothelial effects, and central-nervous-system research applications.

The compound's positioning is distinctive — it is one of the few research peptides in the tissue-repair category with an extended sustained research programme from a single primary research group, providing methodological consistency across the wide range of tissue and injury contexts characterised.

The gut-repair evidence base uses standard preclinical models of gastrointestinal injury — NSAID-induced gastric ulceration, ethanol-induced gastric injury, colitis models, and intestinal ischaemia-reperfusion injury models. Endpoints include histological assessments, tissue-repair markers, functional measures, and molecular assessments including growth-factor expression and vascular-repair markers.

The intervention protocols use short-course peripheral administration of BPC-157 at microgram-range doses. Comparison arms receive vehicle-only control administration or comparator anti-ulcer/anti-inflammatory pharmaceuticals.

The consistent finding across the gut-repair evidence base is accelerated repair of the various gastrointestinal injury contexts in the BPC-157 arm relative to vehicle-control comparisons. Effect sizes are moderate to substantial, with the strongest signals typically in the earlier-post-injury measurement windows and in the more severe injury models.

The wound-healing evidence base extends the pattern into skin-injury, tendon-injury, ligament-injury, and bone-injury models. Vascular-effect characterisation includes preserved endothelial function in injury contexts and reduced vascular-repair time.

The central-nervous-system research applications are more limited in evidence-base depth but include reported effects on brain-injury models, neuropathic-pain models, and behavioural-endpoint measures in various stress-and-injury contexts. These CNS applications provide the primary cognitive-relevance research angle for the compound.

The evidence base is preclinical rather than clinical — human-trial characterisation of BPC-157 is essentially absent, and the compound has not been developed to clinical-trial stage in any indication.

The concentrated single-research-programme origin (Zagreb) means independent replication by non-Sikiric-affiliated research groups is limited relative to the breadth of the reported findings. The generalisability of the reported effects to independent methodological contexts is therefore uncertain.

The wide range of injury contexts and endpoints characterised in a relatively concentrated timeframe reflects an aggressive publication programme; the risk of over-interpretation of specific individual endpoint results is non-trivial.

The Sikiric BPC-157 research programme provides a substantial preclinical tissue-repair evidence base that motivates continued mechanism and translational research interest in the compound. The specific claims about clinical efficacy in humans, however, are not supported by clinical-trial evidence.

For research purposes BPC-157 is well-positioned as a research-tool for probing tissue-repair mechanisms across multiple injury contexts. For clinical purposes the compound is a research chemical without licensed medicinal use in any major jurisdiction; the popular use of BPC-157 in health-and-wellness contexts is not supported by clinical-evidence standards.